Lundar Tryggve, Due-Tønnessen Bernt Johan, Frič Radek, Brandal Petter, Due-Tønnessen Paulina
Departments of1Neurosurgery.
2Oncology, and.
J Neurosurg Pediatr. 2020 Mar 27;26(1):22-26. doi: 10.3171/2020.1.PEDS19700. Print 2020 Jul 1.
Ependymoma is the third most common posterior fossa tumor in children; however, there is a lack of long-term follow-up data on outcomes after surgical treatment of posterior fossa ependymoma (PFE) in pediatric patients. Therefore, the authors sought to investigate the long-term outcomes of children treated for PFE at their institution.
The authors performed a retrospective analysis of outcome data from children who underwent treatment for PFE and survived for at least 5 years.
The authors identified 22 children (median age at the time of surgery 3 years, range 0-18 years) who underwent primary tumor resection of PFE during the period from 1945 to 2014 and who had at least 5 years of observed survival. None of these 22 patients were lost to follow-up, and they represent the long-term survivors (38%) from a total of 58 pediatric PFE patients treated. Nine (26%) of the 34 children treated during the pre-MRI era (1945-1986) were long-term survivors, while the observed 5-year survival rate in the children treated during the MRI era (1987-2014) was 13 (54%) of 24 patients. The majority of patients (n = 16) received adjuvant radiotherapy, and 4 of these received proton-beam irradiation. Six children had either no adjuvant treatment (n = 3) or only chemotherapy as adjuvant treatment (n = 3). Fourteen patients were alive at the time of this report. According to MRI findings, all of these patients were tumor free except 1 patient (age 78 years) with a known residual tumor after 65 years of event-free survival.Repeat resections for residual or recurrent tumor were performed in 9 patients, mostly for local residual disease with progressive clinical symptoms; 4 patients underwent only 1 repeated resection, whereas 5 patients each had 3 or more resections within 15 years after their initial surgery. At further follow-up, 5 of the patients who underwent a second surgery were found to be dead from the disease with or without undergoing additional resections, which were performed from 6 to 13 years after the second procedure. The other 4 patients, however, were tumor free on the latest follow-up MRI, performed from 6 to 27 years after the last resection. Hence, repeated surgery appears to increase the chance of tumor control in some patients, along with modern (proton-beam) radiotherapy. Six of 8 patients with more than 20 years of survival are in a good clinical condition, 5 of them in full-time work and 1 in part-time work.
Pediatric PFE occurs mostly in young children, and there is marked risk for local recurrence among 5-year survivors even after gross-total resection and postoperative radiotherapy. Repeated resections are therefore an important part of treatment and may lead to persistent tumor control. Even though the majority of children with PFE die from their tumor disease, some patients survive for more than 50 years with excellent functional outcome and working capacity.
室管膜瘤是儿童第三常见的后颅窝肿瘤;然而,关于小儿后颅窝室管膜瘤(PFE)手术治疗后结局的长期随访数据匮乏。因此,作者试图调查在其机构接受PFE治疗的儿童的长期结局。
作者对接受PFE治疗且存活至少5年的儿童的结局数据进行了回顾性分析。
作者确定了22名儿童(手术时的中位年龄为3岁,范围0 - 18岁),他们在1945年至2014年期间接受了PFE原发肿瘤切除术,且有至少5年的观察生存期。这22名患者均未失访,他们代表了58名接受治疗的小儿PFE患者中的长期幸存者(38%)。在MRI时代之前(1945 - 1986年)接受治疗的34名儿童中有9名(26%)是长期幸存者,而在MRI时代(1987 - 2014年)接受治疗的24名患者中观察到的5年生存率为13名(54%)。大多数患者(n = 16)接受了辅助放疗,其中4名接受了质子束照射。6名儿童未接受辅助治疗(n = 3)或仅接受化疗作为辅助治疗(n = 3)。在本报告发布时,14名患者存活。根据MRI检查结果,除1名患者(78岁)在无事件生存65年后已知有残留肿瘤外,所有这些患者均无肿瘤。9名患者因残留或复发性肿瘤进行了再次切除,主要是针对伴有进行性临床症状的局部残留病灶;4名患者仅进行了1次再次切除,而5名患者在初次手术后15年内每人进行了3次或更多次切除。在进一步随访中,接受第二次手术的患者中有5名被发现死于该疾病,无论是否进行了额外的切除,这些切除是在第二次手术后6至13年进行的。然而,其他4名患者在最后一次切除后6至27年进行的最新随访MRI检查中无肿瘤。因此,与现代(质子束)放疗一样,再次手术似乎增加了一些患者控制肿瘤的机会。8名存活超过20年的患者中有6名临床状况良好,其中5名全职工作,1名兼职工作。
小儿PFE大多发生于幼儿,即使在全切除及术后放疗后,5年幸存者中局部复发风险仍很高。因此,再次切除是治疗的重要组成部分,可能导致肿瘤的持续控制。尽管大多数患有PFE的儿童死于肿瘤疾病,但一些患者存活超过50年,功能结局和工作能力良好。